600789 鲁抗医药
2025/09 - 九个月2024/122023/122022/122021/12

盈利能力分析
净资产收益率 ROE (%)3.58610.4817.0654.1572.743
总资产报酬率 ROA (%)1.5764.4092.8091.6681.180
投入资产回报率 ROIC (%)1.8825.2953.4252.0231.410

边际利润分析
销售毛利率 (%)21.71323.96324.65522.19123.918
营业利润率 (%)4.1166.9984.4272.6472.356
息税前利润/营业总收入 (%)4.8507.8215.5254.0613.691
净利润/营业总收入 (%)3.1716.5514.1782.5461.826

收益指标分析
经营活动净收益/利润总额(%)105.15861.33087.575110.645114.806
价值变动净收益/利润总额(%)-1.708-1.743-2.639-4.351-2.802
营业外收支净额/利润总额(%)-2.144-0.5270.3080.881-2.148

偿债能力分析
流动比率 (X)1.1961.3491.0370.8500.791
速动比率 (X)0.7980.8640.6370.4910.444
资产负债率 (%)53.44155.35757.49659.81656.176
带息债务/全部投入资本 (%)42.84844.55747.42249.28146.735
股东权益/带息债务 (%)124.596115.868104.10496.474106.707
股东权益/负债合计 (%)83.98677.79771.36264.30174.710
利息保障倍数 (X)5.9139.0975.0962.9192.666

营运能力分析
应收账款周转天数 (天)55.34550.30843.65740.51241.120
存货周转天数 (天)102.593109.766112.194110.63999.794